Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. (RVMD) is a clinical-stage precision oncology company dedicated to discovering and developing innovative targeted therapies that address the unmet needs of cancer patients. The company leverages its proprietary product engine to target frontier oncology pathways, with a strong focus on the RAS and mTOR signaling pathways, which are crucial for cancer growth and survival. Revolution Medicines’ approach draws inspiration from nature and evolution, harnessing insights from natural products to guide the discovery and development of small molecules that modulate key cancer targets.
The company’s research and development pipeline features several promising candidates, including RMC-4630, a SHP2 inhibitor, and a portfolio of RAS(ON) inhibitors such as RMC-6236, RMC-6291, and RMC-9805. These novel therapies aim to inhibit the active form of RAS proteins, which are common drivers in numerous cancer types. Revolution Medicines is also advancing the SOS1 and 4EBP1/mTORC1 programs, which hold significant potential in combination treatment strategies.
Recent achievements highlight the company’s progress in clinical development. Notably, the RMC-6236 Phase 1/1b trial demonstrated promising clinical activity and a favorable safety profile in patients with advanced solid tumors harboring KRAS mutations. The trial results showed an objective response rate of 38% in non-small cell lung cancer (NSCLC) and 20% in pancreatic ductal adenocarcinoma (PDAC), with disease control rates of 85% and 87%, respectively.
In October 2023, Revolution Medicines announced a pivotal milestone with the merger with EQRx, Inc., enhancing its financial position and enabling further investment in its clinical programs. The merger is expected to add approximately $1.1 billion in net cash proceeds, supporting the advancement of their RAS(ON) and RAS Companion Inhibitors. Dr. Sandra Horning, a renowned oncologist and former Genentech executive, joined the board of directors, bringing invaluable experience to the company.
Revolution Medicines continues to engage the scientific community and stakeholders through presentations at major conferences and investor webcasts. The company remains committed to advancing its robust pipeline of oncology therapies, aiming to revolutionize the treatment landscape for RAS-addicted cancers and improve outcomes for cancer patients worldwide.
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology firm, announced its participation in two upcoming investor conferences. CEO Mark A. Goldsmith will speak at the Guggenheim Healthcare Talks 2023 Oncology Conference on February 9, 2023, at 9:00 a.m. Eastern, and at the SVB Securities Global Biopharma Conference on February 16, 2023, at 1:00 p.m. Eastern. The Guggenheim event will take place in-person at the St. Regis New York, while the SVB conference will be virtual. Live webcasts will be accessible through the company’s website, with replays available for 14 days post-conferences.
Revolution Medicines, a clinical-stage oncology firm focusing on targeted therapies for RAS-addicted cancers, announced that CEO Mark A. Goldsmith will present at the 41st Annual J.P. Morgan Healthcare Conference from January 9-12, 2023, in San Francisco. Goldsmith's presentation is scheduled for January 10 at 11:15 a.m. Pacific in the Georgian Room of the Westin St. Francis Hotel. Live access to the presentation will be available on the company's website, and a replay will be accessible for at least 14 days post-conference.
Revolution Medicines (Nasdaq: RVMD) announced the publication of a manuscript in the Journal of Medicinal Chemistry detailing RMC-5552, a bi-steric mTORC1-selective inhibitor. This compound exhibits a remarkable 40-fold selectivity for mTORC1 over mTORC2. Preclinical studies revealed that RMC-5552, in combination with a KRASG12C inhibitor, led to tumor regressions in resistant non-small cell lung cancer models. Phase 1/1b trials for RMC-5552 in patients with refractory solid tumors are ongoing, with promising initial antitumor activity reported.
Revolution Medicines, Inc. (Nasdaq: RVMD) announced the termination of its collaboration with Sanofi for the development of RMC-4630, a SHP2 inhibitor for RAS-addicted cancers. This decision allows Revolution Medicines to regain full control over the drug’s development and commercialization strategies. The transition is expected to occur in the first half of 2023. The company will continue its Phase 2 study of RMC-4630 in combination with sotorasib, providing topline data by late 2023. The projected 2022 GAAP net loss is updated to $245-265 million.
Revolution Medicines, a clinical-stage oncology company (Nasdaq: RVMD), announced participation in two investor conferences. CEO Mark A. Goldsmith will host fireside chats at the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference on November 14, 2022, at 7:00 a.m. Eastern, and the 5th Annual Evercore ISI HealthCONx Conference from November 29 to December 1, 2022, with his chat scheduled for December 1 at 2:15 p.m. Eastern. Webcasts of the chats will be available online, with archived replays for at least 14 days.
Revolution Medicines (RVMD) reported its Q3 2022 financial results, highlighting ongoing Phase 1/1b trials for RMC-6236 and RMC-6291, aimed at treating RAS-addicted cancers. The company completed a public equity financing in July, raising approximately $265 million to enhance its financial position. Q3 revenue stood at $3.4 million, with a net loss of $73.3 million. R&D expenses rose to $69.5 million, driven by clinical trial activities. RVMD maintains a cash position of $655 million, projecting to fund operations through 2024.
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology firm, will report its third-quarter financial results on November 7, 2022, after market close. The company is focused on developing therapies for RAS-addicted cancers, with RMC-6236 and RMC-6291 currently in clinical trials. Senior management will host a webcast at 4:30 p.m. ET on the same day to discuss the financial outcomes and corporate advancements, which will be accessible via their website for 14 days post-event.
Revolution Medicines, Inc. (Nasdaq: RVMD) announced that the first patient has been dosed in its Phase 1/1b clinical trial of RMC-6291, a novel oral, selective KRASG12C(ON) Inhibitor. This trial aims to evaluate the drug's safety and tolerability in patients with advanced solid tumors harboring the KRASG12C mutation. RMC-6291 is the first candidate from Revolution's pipeline of mutant-selective RAS(ON) Inhibitors, followed closely by RMC-6236, its RASMULTI(ON) Inhibitor. The company believes its complementary approaches will be effective against RAS-addicted cancers.
Revolution Medicines (Nasdaq: RVMD) announced key leadership changes, promoting Jack Anders to Chief Financial Officer and Jeff Cislini to General Counsel. Daniel Simon will join as Chief Business Officer. Anders boasts 20 years of finance experience, pivotal in the company's growth into a clinical-stage firm. Cislini brings over 20 years in legal expertise, focusing on governance and compliance. Simon, with 15 years in life sciences, is expected to enhance strategic planning and business development. These appointments aim to strengthen Revolution Medicines' focus on RAS-addicted cancer therapies.
Revolution Medicines, Inc. (Nasdaq: RVMD) announced participation in upcoming investor conferences, with CEO Mark A. Goldsmith set to speak at both events. The 2022 Wells Fargo Healthcare Conference will take place from September 7-9, featuring Goldsmith's fireside chat on September 8 at 3:45 p.m. Eastern. The H.C. Wainwright 24th Annual Global Investment Conference follows from September 12-14, with a chat scheduled for September 12 at 7:00 a.m. Eastern. A webcast of the latter will be available online for 14 days post-event.
FAQ
What is the current stock price of Revolution Medicines (RVMD)?
What is the market cap of Revolution Medicines (RVMD)?
What does Revolution Medicines, Inc. specialize in?
What are some of the key products in Revolution Medicines’ pipeline?
What recent achievements has Revolution Medicines reported?
What is the significance of the RMC-6236 Phase 1/1b trial?
How does the merger with EQRx benefit Revolution Medicines?
Who recently joined the board of Revolution Medicines?
What are RAS(ON) inhibitors?
How does Revolution Medicines generate insights for its drug discovery?
What are some of the ongoing trials at Revolution Medicines?
How can investors stay updated on Revolution Medicines’ developments?
